-transparent.png){kind=logo}
From the results obtained in preliminary in vitro experiments we may conclude that the unspecific breakdown of kininogens by neutral and acidic granulocytic proteinases may occur also in the organism during pathological conditions. Inhibitor application may serve as a valuable tool to prevent unspecific proteolytic degradation and thus elimination of kininogens and other clotting or complement factors from their biological function. Furthermore, specific cleavage products of the kininogens produced by granulocytic enzymes may be useful in the diagnosis of a beginning septicemia as well as in elucidation of the primary structure of the human kininogens.
Related Publications
B Dittman, and
R Wimmer, and
R Mindermann, and
K Ohlsson
January 1986,
Biomedica biochimica acta,
B Dittman, and
R Wimmer, and
R Mindermann, and
K Ohlsson
July 2010,
Biological chemistry,
B Dittman, and
R Wimmer, and
R Mindermann, and
K Ohlsson
January 1988,
Methods in enzymology,
B Dittman, and
R Wimmer, and
R Mindermann, and
K Ohlsson
June 1984,
Clinical nephrology,
B Dittman, and
R Wimmer, and
R Mindermann, and
K Ohlsson
January 1983,
American journal of nephrology,
B Dittman, and
R Wimmer, and
R Mindermann, and
K Ohlsson
September 1976,
Hoppe-Seyler's Zeitschrift fur physiologische Chemie,
B Dittman, and
R Wimmer, and
R Mindermann, and
K Ohlsson
July 1976,
Seminars in thrombosis and hemostasis,
B Dittman, and
R Wimmer, and
R Mindermann, and
K Ohlsson
September 1972,
Research communications in chemical pathology and pharmacology,
B Dittman, and
R Wimmer, and
R Mindermann, and
K Ohlsson
January 1986,
Advances in experimental medicine and biology,
B Dittman, and
R Wimmer, and
R Mindermann, and
K Ohlsson
February 1995,
American journal of kidney diseases : the official journal of the National Kidney Foundation,
